Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BeiGene (BGNE)
NASDAQ:BGNE
Holding BGNE?
Track your performance easily
BGNE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$126.97 - $248.16
Previous Close$246.04
Volume607.53K
Average Volume (3M)301.36K
Market Cap
$25.88B
Enterprise Value$30.88B
Total Cash (Recent Filing)$2.59B
Total Debt (Recent Filing)$7.59B
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Nov 07, 2024EPS Estimate
-$1.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.08
Shares Outstanding106,117,636
10 Day Avg. Volume346,772
30 Day Avg. Volume301,361
Standard Deviation0.14
R-Squared0.05
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)7.76
Price to Sales (P/S)8.01
Price to Cash Flow (P/CF)-64.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.97
Enterprise Value/Gross Profit14.85
Enterprise Value/Ebitda-59.94
Forecast
1Y Price Target
$266.44Price Target Upside8.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
BeiGene News
Bulls Say, Bears Say
Bulls Say
Pipeline And DevelopmentBeiGene's robust pipeline, consisting of 33 products in clinical development and 8 in Phase 3 trials, provides substantial potential upside and future growth opportunities.
Product PerformanceBrukinsa, BeiGene's flagship product, has rapidly taken market share and regularly beaten street expectations, positioning it as a strong performer in the biotech market.
Revenue And Market ShareBrukinsa is on track to generate over $2B for the company, with total revenues expected to reach $3.7B, showcasing its significant revenue potential.
Bears Say
Revenue ForecastThe revenue forecast for the coming years has been slightly lowered due to increasing competition in the BTK inhibitor market in China.
Sales PerformanceSelf-developed drug pamiparib saw a YoY sales decrease of 65.2%.
VolatilityThe rise in beta reflects higher volatility, leading to an increased cost of equity and WACC.
---
Ownership Overview
33.74% Insiders
14.17% Mutual Funds
39.82% Other Institutional Investors
11.21% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BGNE FAQ
What was BeiGene’s price range in the past 12 months?
BeiGene lowest stock price was $126.97 and its highest was $248.16 in the past 12 months.
What is BeiGene’s market cap?
Currently, no data Available
When is BeiGene’s upcoming earnings report date?
BeiGene’s upcoming earnings report date is Nov 07, 2024 which is in 32 days.
How were BeiGene’s earnings last quarter?
BeiGene released its earnings results on Aug 27, 2024. The company reported -$1.15 earnings per share for the quarter, beating the consensus estimate of -$2.189 by $1.039.
Is BeiGene overvalued?
According to Wall Street analysts BeiGene’s price is currently Undervalued.
Does BeiGene pay dividends?
BeiGene does not currently pay dividends.
What is BeiGene’s EPS estimate?
BeiGene’s EPS estimate is -$1.56.
How many shares outstanding does BeiGene have?
BeiGene has 97,341,450 shares outstanding.
What happened to BeiGene’s price movement after its last earnings report?
BeiGene reported an EPS of -$1.15 in its last earnings report, beating expectations of -$2.189. Following the earnings report the stock price went up 1.481%.
Which hedge fund is a major shareholder of BeiGene?
Among the largest hedge funds holding BeiGene’s share is Baker Bros Advisors LP. It holds BeiGene’s shares valued at 2B.
---
BeiGene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$266.44 (8.29% Upside)
$266.44 (8.29% Upside)
Blogger Sentiment
Bullish
BGNE Sentiment 83%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 46.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $159.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.45%
12-Months-Change
Fundamentals
Return on Equity
-14.62%
Trailing 12-Months
Asset Growth
-0.29%
Trailing 12-Months
Company Description
BeiGene
BeiGene, Ltd.is a biopharmaceutical company. The company primarily focuses on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer.
---
BGNE Stock 12 Month Forecast
Average Price Target
$266.44
▲(8.29% Upside)
Technical Analysis
Best Analysts Covering BGNE
1 Year
1 Year Success Rate
10/10 ratings generated profit
1 Year Average Return
+35.41%
assigned a buy rating 6 days ago
Copying Kelly Shi's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +35.41% per trade.
---